Lili Liao

Lili Liao is an accomplished professional with extensive experience in the fields of molecular biology and cancer research. Currently serving as Associate Director and Group Leader at Frontage Laboratories, Inc. since January 2020, Lili Liao specializes in cell-based and non-cell-based neutralizing antibody assays, anti-drug antibody assays, method development, validation, and sample analysis. Prior roles include Research Assistant I at Thomas Jefferson University, where Lili Liao investigated cell death pathways in T cell function, and Research Associate at Yale University, focusing on the epigenetic regulation of tumor growth in kidney cancer. Lili Liao's earlier experience encompasses postdoctoral research at both Thomas Jefferson University and Cleveland Clinic, emphasizing epigenetic regulation in renal cancer and broader cancer studies. Lili Liao holds a PhD in Molecular Biology from the Chinese Academy of Sciences and a Bachelor's degree in Microbiology from Wuhan University.